Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000597851 | SCV000703994 | uncertain significance | not provided | 2017-12-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001348148 | SCV001542436 | uncertain significance | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2022-08-19 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 840 of the CC2D2A protein (p.Ile840Thr). This variant is present in population databases (rs373111926, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with CC2D2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 498793). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000597851 | SCV002762465 | uncertain significance | not provided | 2022-08-22 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26415585) |
Ambry Genetics | RCV003343931 | SCV004051622 | uncertain significance | Inborn genetic diseases | 2023-08-16 | criteria provided, single submitter | clinical testing | The c.2519T>C (p.I840T) alteration is located in exon 21 (coding exon 19) of the CC2D2A gene. This alteration results from a T to C substitution at nucleotide position 2519, causing the isoleucine (I) at amino acid position 840 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005027701 | SCV005662424 | uncertain significance | Meckel syndrome, type 6; Joubert syndrome 9; COACH syndrome 2; Retinitis pigmentosa 93 | 2024-06-07 | criteria provided, single submitter | clinical testing |